Skip to content

Multi-institutional comparative test of TRM-108

Multi-institutional comparative test of TRM-108 - Multi-institutional comparative test of TRM-108

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008478
Enrollment
110
Registered
2012-07-23
Start date
2012-07-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients requiring a postoperative Total Parenteral Nutrition.

Interventions

TRM-108 Group Take 24 hours to administer a one-days dose by continuous intravenous infusion via central vein.The administration period is 7 days. FC Group Take 24 hours to administer a one-days do

Sponsors

terumo corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Patients aged at least 20 years. (2)Patients requiring a postoperative Total Parenteral Nutrition. (3)Patients who can give informed consent themelves betes mellitus or writing.

Exclusion criteria

Exclusion criteria: (1)Investigators have juged that patient coresponds to any of the following. lactic acidemia/addison's disease/oliguria/azotemia/hypothyroidism/hypothyroidism/heoatic coma or possibility of hepatic coma/defect in metabolism of amino asid/hemophiliac/medical historyl of hypersensitivity in any of the ingredient of investigational drug/electrolyte imbalance/severe liver damage/severe renal dysfunction/severe diabestesbmellitus or gucose metabolism disorder (2)Woman during pregnancy or breastfeeding (3)patient who have participated in another clinicaltrial trail whthin 6months beforths befor the enrollment for this trial. (4)Investigators have juged that patient have an inappropriate medical condition to particioate in this trial.

Design outcomes

Primary

MeasureTime frame
Total protein,Albumin, Transferrin,Prealbumin, Retinol Binding Protein

Countries

Japan

Contacts

Public ContactAtsuko suzuki

terumo corporation Clinical Development Department

atsuko_suzuki@terumo.co.jp0465-81-8488

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026